Trial Profile

Intravenous Administration of Autoserum-cultured Autologous Mesenchymal Stem Cells in Ischemic Stroke: A Single Center, Randomized, Open Label, Prospective, Phase 3 Study

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous mesenchymal stem cell therapy Pharmicell (Primary)
Indications Stroke
Focus Registrational; Therapeutic Use
Acronyms STARTING-2
Sponsors Pharmicell

Most Recent Events

28 Mar 2022 Primary endpoint (Circulating factors that are associated with the clinical improvement in the Fugl-Meyer Assessment) has been met according to the results published in the stroke
28 Mar 2022 Status changed from recruiting to completed.
28 Mar 2022 Results published in the Stroke

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com